Acute psychotropic effects of oral cannabis extract with a defined content of Delta9-tetrahydrocannabinol (THC) in healthy volunteers [0.03%]
口服大麻提取物（定义了Delta9-四氢大麻酚（THC）含量）在健康志愿者中的急性精神活性作用
R M Kaufmann,B Kraft,R Frey et al.
R M Kaufmann et al.
Introduction: The medical use of cannabinoids is limited mainly by their undesirable effects. With respect to acute psychotropic effects, the aim of this study is the comparison of an oral cannabis extract and low-dose di...
Clinical Trial
Pharmacopsychiatry. 2010 Jan;43(1):24-32. DOI:10.1055/s-0029-1237397 2010
Antipsychotic use patterns in persons initially treated with mood stabilizers: a naturalistic study [0.03%]
一项自然研究：最初使用情绪稳定剂治疗的精神病患者群体的抗精神病药物使用模式
H Verdoux,A Cougnard,G-R Auleley et al.
H Verdoux et al.
Introduction: Little information is available on the pattern of use of antipsychotics in naturalistic conditions in persons initially treated with "conventional" mood stabilizers (lithium and anticonvulsants). ...
D R Bach,J Kindler,W K Strik
D R Bach
Introduction: Mild unconjugated hyperbilirubinemia seems to be more common in patients with disorders from the schizophrenic spectrum than in other psychiatric patients or in the general population and has been linked to ...
Neutropenia induced by second generation antipsychotics: a prospective investigation [0.03%]
第二代抗精神病药所致中性粒细胞减少症的一项前瞻性调查研究
M A Rettenbacher,A Hofer,G Kemmler et al.
M A Rettenbacher et al.
Background: Clozapine is known to induce neutropenia as well as agranulocytosis. Some cases of olanzapine- and risperidone-induced neutropenia and agranulocytosis have also been reported. We prospectively investigated sch...
Comparative Study
Pharmacopsychiatry. 2010 Mar;43(2):41-4. DOI:10.1055/s-0030-1249071 2010
Does oral antipsychotic pre-treatment influence outcome of a switch to long-acting injectable risperidone in patients with schizophrenia? [0.03%]
口服抗精神病药的预处理会影响换用利培酮长效注射剂治疗精神分裂症患者的疗效吗？
M Schmauss,B Diekamp,M Gerwe et al.
M Schmauss et al.
Introduction: The objective of this open-label study was to evaluate treatment benefits of risperidone long-acting injectable (RLAI) in patients with schizophrenia following direct transition from oral risperidone (RIS) c...
Clinical Trial
Pharmacopsychiatry. 2010 Mar;43(2):73-80. DOI:10.1055/s-0029-1239592 2010
Reduction of Prepulse Inhibition (PPI) after neonatal excitotoxic lesion of the ventral thalamus in pubertal and adult rats [0.03%]
青春期和成年期大鼠腹侧丘脑兴奋性损伤后前脉抑制(PPI)的降低
R Wolf,K Matzke,K Paelchen et al.
R Wolf et al.
Background: Growing evidence indicates the role of the thalamus in schizophrenia. The ventral part of the thalamus has been investigated in a few post-mortem studies, suggesting a possible neurodevelopmental etiology of t...
The tolerability of rTMS treatment in schizophrenia with respect to cognitive function [0.03%]
关于精神分裂症经颅磁刺激治疗耐受性的认知功能研究
M Mittrach,J Thünker,G Winterer et al.
M Mittrach et al.
Introduction: The purpose of this study was to assess tolerability and safety of high-frequency rTMS with regard to cognitive performance when conducted as "add-on" treatment in chronic schizophrenia in-patients (n=32). ...
Randomized Controlled Trial
Pharmacopsychiatry. 2010 May;43(3):110-7. DOI:10.1055/s-0029-1242824 2010
Psychopathological rating scales as efficacy parameters in adult ADHD treatment investigations - benchmarking instruments for international multicentre trials [0.03%]
注意缺陷多动障碍成人患者治疗研究中的疗效评价工具——国际多中心试验的基准选择
M Rösler,W Retz,R-D Stieglitz
M Rösler
Introduction: The selection of appropriate instruments in clinical studies is an essential point to detect the effects of pharmacological and/or psychotherapeutic treatments. ...
H Müller,H B Huttner,M Köhrmann et al.
H Müller et al.
Case Reports
Pharmacopsychiatry. 2010 Jun;43(4):152-3. DOI:10.1055/s-0029-1243252 2010
R Tutuncu,H Gunay
R Tutuncu
Case Reports
Pharmacopsychiatry. 2010 May;43(3):119-20. DOI:10.1055/s-0029-1243251 2010